Acquisition · 23 September 2024Redcliffe LabsOmnichannel diagnostics service providerredcliffelabs.com ↗
AcquisitionHealthcare & Life Sciences
Redcliffe Labs acquires Celara Diagnostics for ₹60 crore
By Abha Lohia · Editor ·
Redcliffe Labs: revenue and funding and every story →
- Redcliffe Labs is an omnichannel diagnostics provider with over 80 labs and 2,000 collection centres
- It has acquired Bengaluru-based Celara Diagnostics for up to ₹60 crore ($7 million), its second diagnostics buy in 2024
- The deal follows a $42 million Series C raise and aligns with its strategy to acquire profitable labs to boost cash flow
What happened
- Redcliffe Labs has acquired Celara Diagnostics for up to ₹60 crore ($7 million).
- The acquisition is Redcliffe Labs' second diagnostics acquisition in 2024.
- Redcliffe Labs' board passed a resolution approving the purchase of Celara Diagnostics shares.
- Celara Diagnostics is a Bengaluru-based diagnostics chain offering radiology and pathology services.
- Its services include MRI, CT scans, ultrasonography, neurology, cardiology, and gastroenterology.
- Celara Diagnostics reported FY23 revenue of ₹25 crore and profit of ₹1.5 crore.
- Earlier in 2024, Redcliffe Labs-owned Medicentre acquired Kota-based Prime Sonography & Diagnostic Centre.
Why it matters
- Redcliffe Labs raised a $42 million Series C led by IFU, a Denmark-based investment firm.
- The company plans to use Series C funds to open more labs and collection centres in tier II and III cities.
- Founder Dheeraj Jain stated in March 2024 that Redcliffe aims to acquire labs with strong financial performance to boost cash flow and profitability.
- Redcliffe Labs competes with Thyrocare, Healthians, 1mg, and Dr. Lal PathLabs.
The business
- Redcliffe Labs is an omnichannel diagnostics service provider with 80+ self-owned labs and 2,000+ collection centres.
- It has touched 1 crore+ lives and employs 1,500+ trained phlebotomists.
- It offers doctor-curated health checkup packages, smart reports with colour-coded insights, expert consultation, AI assistance, and diet plans.
- Redcliffe Labs provides home sample collection with temperature-controlled bags and MD pathologist-verified reports.
- It offers Femcliffe (India's first she-centric diagnostic platform), GeneCliffe (DNA/genetic testing), and HealthEx (curated genetic test).
- The company has health calculators for BMI, heart health, pre-diabetic risk, vitamin D, and fever symptoms.
- Redcliffe Labs offers a 100% report accuracy or money-back guarantee.
The founders
DJ
Dheeraj Jain
Founder- Stated in March 2024 that Redcliffe aims to acquire labs with strong financial performance to boost cash flow and profitability.
In numbers
₹60 croreAcquisition amount · 2024
₹25 croreCelara Diagnostics FY23 revenue · 2023
₹1.5 croreCelara Diagnostics FY23 profit · 2023
₹347 croreRedcliffe Labs FY23 revenue · 2023
₹345.6 croreRedcliffe Labs FY23 loss · 2023
$42 millionSeries C raised · 2024
1 crore+Lives touched
80+Self-owned labs
2,000+Collection centres
What happens next
- Redcliffe Labs plans to use Series C funds to open more labs and collection centres, especially in tier II and III cities.
Earlier rounds
- 2024 · Series C · $42 million · led by IFU
Up against
ThyrocareHealthians1mgDr. Lal PathLabs
Words to know
- omnichannel
- providing services through multiple channels (online, offline, home collection) seamlessly
- phlebotomist
- a trained professional who draws blood from patients for medical tests
- Series C
- a later-stage funding round for scaling operations, typically after Series A and B
The numbers around it
Redcliffe Labs has 4 funding rounds in StopDown's archive, $115 Mn raised in all.
| When | Round | Amount | Led by |
|---|---|---|---|
| 17 September 2024 | Series C | $42M | IFU (Denmark's Investment Fund for Developing Countries) |
| 13 August 2023 | growth | $80 million | |
| 29 September 2022 | Series B | $100-125 million | |
| 6 May 2022 | Series B | $61M | LeapFrog Investments |
Terms in this story
- Funding stage: Startups raise money in steps called funding stages: pre-seed, seed, Series A, B, C and later, ending in a listing or a sale. Each step is larger and asks for more proof. In India, Series A rounds run from a few million dollars to about $15 million, as of November 2026.
- Series B/C: Series B, C, D and later rounds are growth rounds: large cheques for a startup with a proven model that wants to expand, enter new markets or move toward profit and a listing. In India they are usually priced in CCPS and, when foreign investors take part, must follow FEMA pricing rules.
- Mergers and acquisitions: An acquisition is when one company buys another, and a merger is when two companies combine into one. For most Indian startups a sale is a likelier exit than an IPO, and the Competition Commission of India (CCI) must approve deals that cross its asset, turnover or ₹2,000 crore deal-value limits.
- Profitability: A path to profitability is the plan and evidence that a startup will earn more than it spends. In India the usual order is contribution positive, then EBITDA positive, then net profit and positive cash flow. Each step is a different test, so claims of profit need the definition.
Read next
FundingRedcliffe Lifetech raises $61 million Series BRedcliffe Lifetech is an omnichannel diagnostics platform offering 3,500+ pathology and genetic testsFundingAugust AI raises $12M for US expansionAugust AI offers an AI health assistant that answers medical questions through WhatsApp and a mobile appFundingVitusCare raises $3 million Series BVitusCare runs dialysis units inside partner hospitals, which keeps costs low, and has grown from 22 to over 60 centres
Everything on Redcliffe Labs → · All startup news on 23 September 2024 →
Is this Redcliffe Labs? Get your “Featured on StopDown” badge →